Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Oramed Pharm ( (ORMP) ).
On February 7, 2025, Oramed Pharmaceuticals entered into a Supplemental Agreement to amend a Joint Venture Agreement with Hefei Tianhui Biotech Co., Ltd. to spin off its Protein Oral Delivery (POD™) technology into a new entity, OraTech Pharmaceuticals Inc. This move aims to accelerate the development and commercialization of oral insulin and other POD™ technology-based drugs, with both Oramed and HTIT contributing a combined $75 million. The transaction is expected to enhance Oramed’s market position by leveraging HTIT’s manufacturing capabilities and ensuring robust financial resources to support further clinical and regulatory advancements, potentially redefining diabetes care.
More about Oramed Pharm
Oramed Pharmaceuticals is a clinical-stage pharmaceutical company specializing in oral drug delivery solutions, with its innovative Protein Oral Delivery (POD™) technology designed to protect drug integrity and enhance absorption. The company focuses on developing oral forms of drugs traditionally given via injections, particularly for diabetes management, and operates in the United States and Israel.
YTD Price Performance: -9.96%
Average Trading Volume: 158,374
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $87.48M
For detailed information about ORMP stock, go to TipRanks’ Stock Analysis page.
